Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2014 (2014), Article ID 920134, 12 pages
http://dx.doi.org/10.1155/2014/920134
Review Article

The Role of MicroRNAs in Diabetic Nephropathy

1Department of Nephrology, The Second Hospital of Jilin University, 218 Ziqiang Street, Changchun 130041, China
2Chinese-American Research Institute for Diabetic Complications at Wenzhou Medical University, Wenzhou 325035, China
3Kosair Children’s Hospital Research Institute, Department of Pediatrics, University of Louisville, Louisville, KY 40202, USA
4Cardiovascular Center, The First Hospital of Jilin University, Changchun 130021, China
5State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Shanghai 200031, China

Received 7 June 2014; Accepted 29 July 2014; Published 1 September 2014

Academic Editor: Konstantinos Papatheodorou

Copyright © 2014 Hao Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Dronavalli, I. Duka, and G. L. Bakris, “The pathogenesis of diabetic nephropathy,” Nature Clinical Practice Endocrinology and Metabolism, vol. 4, no. 8, pp. 444–452, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. M. L. Alvarez and J. K. DiStefano, “The role of non-coding RNAs in diabetic nephropathy: potential applications as biomarkers for disease development and progression,” Diabetes Research and Clinical Practice, vol. 99, no. 1, pp. 1–11, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. M. Sun, Y. Su, J. Li, and L. Wang, “Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy,” Biochemical and Biophysical Research Communications, vol. 433, no. 4, pp. 359–361, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Y. Chen, X. Zhong, X. Huang et al., “MicroRNA-29b inhibits diabetic nephropathy in db/db mice,” Molecular Therapy, vol. 22, no. 4, pp. 842–853, 2013. View at Google Scholar
  5. W. B. Reeves and T. E. Andreoli, “Transforming growth factor β contributes to progressive diabetic nephropathy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 14, pp. 7667–7669, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. F. N. Ziyadeh and K. Sharma, “Overview: combating diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 14, no. 5, pp. 1355–1357, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Dey, N. Ghosh-Choudhury, B. S. Kasinath, and G. G. Choudhury, “TGFβ-stimulated microRNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion,” PLoS ONE, vol. 7, no. 8, Article ID e42316, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. S. L. Habib, M. Yadav, S. Tizani, B. Bhandari, and A. J. Valente, “Tuberin inhibits production of the matrix protein fibronectin in diabetes,” Journal of the American Society of Nephrology, vol. 23, no. 10, pp. 1652–1662, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Adhikary, F. Chow, D. J. Nikolic-Paterson et al., “Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy,” Diabetologia, vol. 47, no. 7, pp. 1210–1222, 2004. View at Google Scholar · View at Scopus
  10. N. Sakai, T. Wada, K. Furuichi et al., “Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy,” The American Journal of Kidney Diseases, vol. 45, no. 1, pp. 54–65, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. C. L. Lin, F. Wang, Y. Kuo, Y. Huang, H. Huang, and Y. Sun, “Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuries,” Kidney International, vol. 69, no. 9, pp. 1593–1600, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Zhang, S. Pang, B. Deng et al., “High glucose induces renal mesangial cell proliferation and fibronectin expression through JNK/NF-κB/NADPH oxidase/ROS pathway, which is inhibited by resveratrol,” International Journal of Biochemistry and Cell Biology, vol. 44, no. 4, pp. 629–638, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Pan, X. Zhang, Y. Wang et al., “Targeting JNK by a new curcumin analog to inhibit NF-kB-mediated expression of cell adhesion molecules attenuates renal macrophage infiltration and injury in diabetic mice,” PLoS ONE, vol. 8, no. 11, Article ID e79084, 2013. View at Publisher · View at Google Scholar
  14. S. Bhattacharya, P. Manna, R. Gachhui, and P. C. Sil, “D-Saccharic acid 1,4-lactone protects diabetic rat kidney by ameliorating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via NF-κB and PKC signaling,” Toxicology and Applied Pharmacology, vol. 267, no. 1, pp. 16–29, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. S. M. Ka, Y. C. Yeh, X. R. Huang et al., “Kidney-targeting Smad7 gene transfer inhibits renal TGF-β/MAD homologue (SMAD) and nuclear factor κb (NF-κB) signalling pathways, and improves diabetic nephropathy in mice,” Diabetologia, vol. 55, no. 2, pp. 509–519, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. X. Xie, J. Peng, X. Chang et al., “Activation of RhoA/ROCK regulates NF-κB signaling pathway in experimental diabetic nephropathy,” Molecular and Cellular Endocrinology, vol. 369, no. 1-2, pp. 86–97, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Bhatt, Q. S. Mi, and Z. Dong, “MicroRNAs in kidneys: biogenesis, regulation, and pathophysiological roles,” American Journal of Physiology—Renal Physiology, vol. 300, no. 3, pp. F602–F610, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. S. L. Fernandez-Valverde, R. J. Taft, and J. S. Mattick, “MicroRNAs in β-cell biology, insulin resistance, diabetes and its complications,” Diabetes, vol. 60, no. 7, pp. 1825–1831, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. J. H. Chua, A. Armugam, and K. Jeyaseelan, “MicroRNAs: biogenesis, function and applications,” Current Opinion in Molecular Therapeutics, vol. 11, no. 2, pp. 189–199, 2009. View at Google Scholar · View at Scopus
  20. V. N. Kim, J. Han, and M. C. Siomi, “Biogenesis of small RNAs in animals,” Nature Reviews Molecular Cell Biology, vol. 10, no. 2, pp. 126–139, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. P. D. Zamore and B. Haley, “Ribo-gnome: the big world of small RNAs,” Science, vol. 309, no. 5740, pp. 1519–1524, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Kato, L. Arce, M. Wang, S. Putta, L. Lanting, and R. Natarajan, “A microRNA circuit mediates transforming growth factor-β1 autoregulation in renal glomerular mesangial cells,” Kidney International, vol. 80, no. 4, pp. 358–368, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Dey, F. Das, M. M. Mariappan et al., “MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes,” The Journal of Biological Chemistry, vol. 286, no. 29, pp. 25586–25603, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Kato, J. Zhang, M. Wang et al., “MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-β-induced collagen expression via inhibition of E-box repressors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 9, pp. 3432–3437, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Kato, V. Dang, M. Wang et al., “TGF-β induces acetylation of chromatin and of Ets-1 to alleviate repression of miR-192 in diabetic nephropathy,” Science Signaling, vol. 6, no. 278, article ra43, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Putta, L. Lanting, G. Sun, G. Lawson, M. Kato, and R. Natarajan, “Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 23, no. 3, pp. 458–469, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Wang, M. Herman-Edelstein, P. Koh et al., “E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-β,” Diabetes, vol. 59, no. 7, pp. 1794–1802, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Kato, S. Putta, M. Wang et al., “TGF-β activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN,” Nature Cell Biology, vol. 11, no. 7, pp. 881–889, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Kato, L. Wang, S. Putta et al., “Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-β-induced collagen expression in kidney cells,” The Journal of Biological Chemistry, vol. 285, no. 44, pp. 34004–34015, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. J. T. Park, M. Kato, H. Yuan et al., “FOG2 protein down-regulation by transforming growth factor-β1-induced MicroRNA-200b/c leads to akt kinase activation and glomerular mesangial hypertrophy related to diabetic nephropathy,” The Journal of Biological Chemistry, vol. 288, no. 31, pp. 22469–22480, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Bakirtzi, M. Hatziapostolou, I. Karagiannides et al., “Neurotensin signaling activates microRNAs-21 and -155 and Akt, promotes tumor growth in mice, and is increased in human colon tumors,” Gastroenterology, vol. 141, no. 5, pp. 1749.e1–1761.e1, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Darido, S. Georgy, T. Wilanowski et al., “Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis,” Cancer Cell, vol. 20, no. 5, pp. 635–648, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. F. J. Sheedy, E. Palsson-Mcdermott, E. J. Hennessy et al., “Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21,” Nature Immunology, vol. 11, no. 2, pp. 141–147, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. X. Zhong, A. C. K. Chung, H. Y. Chen et al., “MiR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes,” Diabetologia, vol. 56, no. 3, pp. 663–674, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Fiorentino, M. Cavalera, M. Mavilio et al., “Regulation of TIMP3 in diabetic nephropathy: a role for microRNAs,” Acta Diabetologica, vol. 50, no. 6, pp. 965–969, 2013. View at Google Scholar
  36. R. Basu, J. Lee, Z. Wang et al., “Loss of TIMP3 selectively exacerbates diabetic nephropathy,” The American Journal of Physiology: Renal Physiology, vol. 303, no. 9, pp. F1341–F1352, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Wang, Y. Gao, M. Ma et al., “Effect of miR-21 on renal fibrosis by regulating MMP-9 and TIMP1 in kk-ay diabetic nephropathy mice,” Cell Biochemistry and Biophysics, vol. 67, no. 2, pp. 537–546, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. Q. Wang, Y. Wang, A. W. Minto et al., “MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy,” The FASEB Journal, vol. 22, no. 12, pp. 4126–4135, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. J. D. Beckman, C. Chen, J. Nguyen et al., “Regulation of heme oxygenase-1 protein expression by miR-377 in combination with miR-217,” The Journal of Biological Chemistry, vol. 286, no. 5, pp. 3194–3202, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. S. C. Lee, S. H. Han, J. J. Li et al., “Induction of heme oxygenase-1 protects against podocyte apoptosis under diabetic conditions,” Kidney International, vol. 76, no. 8, pp. 838–848, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Li, L. Zhang, F. Wang et al., “Attenuation of glomerular injury in diabetic mice with tert- butylhydroquinone through nuclear factor erythroid 2-related factor 2-dependent antioxidant gene activation,” American Journal of Nephrology, vol. 33, no. 4, pp. 289–297, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Q. Chen, X. Wang, X. Yao et al., “MicroRNA-195 promotes apoptosis in mouse podocytes via enhanced caspase activity driven by BCL2 insufficiency,” The American Journal of Nephrology, vol. 34, no. 6, pp. 549–559, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. Q. Chen, X. X. Wang, X. M. Yao et al., “Abated microRNA-195 expression protected mesangial cells from apoptosis in early diabetic renal injury in mice,” Journal of Nephrology, vol. 25, no. 4, pp. 566–576, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Mortuza, B. Feng, and S. Chakrabarti, “miR-195 regulates SIRT1-mediated changes in diabetic retinopathy,” Diabetologia, vol. 57, no. 5, pp. 1037–1046, 2014. View at Google Scholar
  45. E. Bible, “Diabetic nephropathy: Sirt1 attenuates diabetic albuminuria,” Nature Reviews Nephrology, vol. 9, no. 12, p. 696, 2013. View at Publisher · View at Google Scholar
  46. K. Huang, J. Huang, X. Xie et al., “Sirt1 resists advanced glycation end products-induced expressions of fibronectin and TGF-beta1 by activating the Nrf2/ARE pathway in glomerular mesangial cells,” Free Radical Biology & Medicine, vol. 65, pp. 528–540, 2013. View at Publisher · View at Google Scholar
  47. M. Kitada, S. Kume, N. Imaizumi, and D. Koya, “Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway,” Diabetes, vol. 60, no. 2, pp. 634–643, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Liu, Y. Zhong, X. Li et al., “Role of transcription factor acetylation in diabetic kidney disease,” Diabetes, vol. 63, no. 7, pp. 2440–2453, 2014. View at Publisher · View at Google Scholar
  49. J. Mu, Q. Pang, Y. Guo et al., “Functional implications of microRNA-215 in TGF-β1-induced phenotypic transition of mesangial cells by targeting CTNNBIP1,” PLoS ONE, vol. 8, no. 3, Article ID e58622, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Sachs and A. Sonnenberg, “Cell-matrix adhesion of podocytes in physiology and disease,” Nature Reviews Nephrology, vol. 9, no. 4, pp. 200–210, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Li, Z. Lu, J. Jia, Z. Zheng, and S. Lin, “Changes in microRNAs associated with podocytic adhesion damage under mechanical stress,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 14, no. 2, pp. 97–102, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. M. L. Alvarez, M. Khosroheidari, E. Eddy, and J. Kiefer, “Role of microRNA 1207-5P and its host gene, the long non-coding RNA Pvt1, as mediators of extracellular matrix accumulation in the kidney: implications for diabetic nephropathy,” PLoS ONE, vol. 8, no. 10, Article ID e77468, 2013. View at Google Scholar
  53. F. He, F. Peng, X. Xia et al., “MiR-135a promotes renal fibrosis in diabetic nephropathy by regulating TRPC1,” Diabetologia, vol. 57, no. 8, pp. 1726–1736, 2014. View at Publisher · View at Google Scholar
  54. B. Wang, P. Koh, C. Winbanks et al., “MiR-200a prevents renal fibrogenesis through repression of TGF-β2 expression,” Diabetes, vol. 60, no. 1, pp. 280–287, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Wei, Y. Zhang, Y. Luo et al., “Aldose reductase regulates miR-200a-3p/141-3p to coordinate Keap1-Nrf2, Tgfbeta1/2, and Zeb1/2 signaling in renal mesangial cells and the renal cortex of diabetic mice,” Free Radical Biology & Medicine, vol. 67, pp. 91–102, 2014. View at Google Scholar
  56. B. Wang, R. Komers, R. Carew et al., “Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis,” Journal of the American Society of Nephrology, vol. 23, no. 2, pp. 252–265, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. B. Du, L. Ma, M. Huang et al., “High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells,” FEBS Letters, vol. 584, no. 4, pp. 811–816, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. C. L. Lin, P. H. Lee, and Y. C. Hsu, “MicroRNA-29a promotion of nephrin acetylation ameliorates hyperglycemia-induced podocyte dysfunction,” Journal of the American Society of Nephrology, vol. 25, no. 8, pp. 1698–1709, 2014. View at Publisher · View at Google Scholar
  59. J. Long, Y. Wang, W. Wang, B. H. J. Chang, and F. R. Danesh, “MicroRNA-29c is a signature MicroRNA under high glucose conditions that targets sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy,” The Journal of Biological Chemistry, vol. 286, no. 13, pp. 11837–11848, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. Z. Zhang, X. Luo, S. Ding et al., “MicroRNA-451 regulates p38 MAPK signaling by targeting of Ywhaz and suppresses the mesangial hypertrophy in early diabetic nephropathy,” The FEBS Letters, vol. 586, no. 1, pp. 20–26, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. D. Yu, C. O. Dos Santos, G. Zhao et al., “miR-451 protects against erythroid oxidant stress by repressing 14-3-3ζ,” Genes and Development, vol. 24, no. 15, pp. 1620–1633, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. H. P. Li, X. C. Zeng, B. Zhang et al., “miR-451 inhibits cell proliferation in human hepatocellular carcinoma through direct suppression of IKK-beta,” Carcinogenesis, vol. 34, no. 11, pp. 2443–2451, 2013. View at Google Scholar
  63. X. Zhang, X. Wang, H. Zhu et al., “Synergistic effects of the GATA-4-mediated miR-144/451 cluster in protection against simulated ischemia/reperfusion-induced cardiomyocyte death,” Journal of Molecular and Cellular Cardiology, vol. 49, no. 5, pp. 841–850, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Kato, H. Yuan, Z. Xu et al., “Role of the Akt/FoxO3a pathway in TGF-β1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease,” Journal of the American Society of Nephrology, vol. 17, no. 12, pp. 3325–3335, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Cheng, X. Fan, G. W. Moeckel, and R. C. Harris, “Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression,” Journal of the American Society of Nephrology, vol. 22, no. 7, pp. 1240–1251, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. Y. Fu, Y. Zhang, Z. Wang et al., “Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy,” American Journal of Nephrology, vol. 32, no. 6, pp. 581–589, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Long, Y. Wang, W. Wang, B. H. J. Chang, and F. R. Danesh, “Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions,” The Journal of Biological Chemistry, vol. 285, no. 30, pp. 23457–23465, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. B. Wang, J. C. Jha, S. Hagiwara et al., “Transforming growth factor-β1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b,” Kidney International, vol. 85, no. 2, pp. 352–361, 2014. View at Publisher · View at Google Scholar
  69. V. Schaeffer, K. M. Hansen, D. R. Morris, R. C. LeBoeuf, and C. K. Abrass, “RNA-binding protein IGF2BP2/IMP2 is required for laminin-β2 mRNA translation and is modulated by glucose concentration,” The American Journal of Physiology—Renal Physiology, vol. 303, no. 1, pp. F75–F82, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. M. S. Ebert and P. A. Sharp, “MicroRNA sponges: progress and possibilities,” RNA, vol. 16, no. 11, pp. 2043–2050, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. J. Stenvang, A. Petri, M. Lindow, S. Obad, and S. Kauppinen, “Inhibition of microRNA function by antimiR oligonucleotides,” Silence, vol. 3, no. 1, article 1, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. C. C. Esau, “Inhibition of microRNA with antisense oligonucleotides,” Methods, vol. 44, no. 1, pp. 55–60, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Davis, S. Propp, S. M. Freier et al., “Potent inhibition of microRNA in vivo without degradation,” Nucleic Acids Research, vol. 37, no. 1, pp. 70–77, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. C. C. Esau and B. P. Monia, “Therapeutic potential for microRNAs,” Advanced Drug Delivery Reviews, vol. 59, no. 2-3, pp. 101–114, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Petersen and J. Wengel, “LNA: a versatile tool for therapeutics and genomics,” Trends in Biotechnology, vol. 21, no. 2, pp. 74–81, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. J. Stenvang and S. Kauppinen, “MicroRNAs as targets for antisense-based therapeutics,” Expert Opinion on Biological Therapy, vol. 8, no. 1, pp. 59–81, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. D. A. Braasch and D. R. Corey, “Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA,” Chemistry and Biology, vol. 8, no. 1, pp. 1–7, 2001. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Davis, B. Lollo, S. Freier, and C. Esau, “Improved targeting of miRNA with antisense oligonucleotides,” Nucleic Acids Research, vol. 34, no. 8, pp. 2294–2304, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Ali, A. Ahmad, S. Banerjee et al., “Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF,” Cancer Research, vol. 70, no. 9, pp. 3606–3617, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Sheth, S. Jajoo, T. Kaur et al., “Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway,” PLoS ONE, vol. 7, no. 12, Article ID e51655, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. M. S. Ebert, J. R. Neilson, and P. A. Sharp, “MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells,” Nature Methods, vol. 4, no. 9, pp. 721–726, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. A. Care, D. Catalucci, F. Felicetti et al., “MicroRNA-133 controls cardiac hypertrophy,” Nature Medicine, vol. 13, no. 5, pp. 613–618, 2007. View at Google Scholar
  83. F. Ma, S. Xu, X. Liu et al., “The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ,” Nature Immunology, vol. 12, no. 9, pp. 861–869, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Valastyan, F. Reinhardt, and N. Benaich, “A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis,” Advances in Breast Cancer, vol. 137, no. 6, pp. 1032–1046, 2009. View at Google Scholar
  85. S. Shi, L. Yu, C. Chiu et al., “Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis,” Journal of the American Society of Nephrology, vol. 19, no. 11, pp. 2159–2169, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. J. Ho, H. N. Kar, S. Rosen, A. Dostal, R. I. Gregory, and J. A. Kreidberg, “Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury,” Journal of the American Society of Nephrology, vol. 19, no. 11, pp. 2069–2075, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. S. D. Deshpande, S. Putta, M. Wang et al., “Transforming growth factor-beta-induced cross talk between p53 and a microRNA in the pathogenesis of diabetic nephropathy,” Diabetes, vol. 62, no. 9, pp. 3151–3162, 2013. View at Google Scholar
  88. B. N. Chau, C. Xin, J. Hartner et al., “MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways,” Science Translational Medicine, vol. 4, no. 121, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. J. C. Henry, A. C. P. Azevedo-Pouly, and T. D. Schmittgen, “MicroRNA replacement therapy for cancer,” Pharmaceutical Research, vol. 28, no. 12, pp. 3030–3042, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. H. Ling, M. Fabbri, and G. A. Calin, “MicroRNAs and other non-coding RNAs as targets for anticancer drug development,” Nature Reviews Drug Discovery, vol. 12, no. 11, pp. 847–865, 2013. View at Google Scholar
  91. F.-F. Lan, H. Wang, Y.-C. Chen et al., “Hsa-let-7g inhibits proliferation of hepatocellular carcinoma cells by downregulation of c-Myc and upregulation of p16INK4A,” International Journal of Cancer, vol. 128, no. 2, pp. 319–331, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. C. Liu, K. Kelnar, B. Liu et al., “The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44,” Nature Medicine, vol. 17, no. 2, pp. 211–215, 2011. View at Publisher · View at Google Scholar
  93. H. Su, J. Yang, T. Xu et al., “MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity,” Cancer Research, vol. 69, no. 3, pp. 1135–1142, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. Y. Xiong, J. Fang, J. Yun et al., “Effects of microrna-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma,” Hepatology, vol. 51, no. 3, pp. 836–845, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. Z. Liu, A. Sall, and D. Yang, “MicroRNA: an emerging therapeutic target and intervention tool,” International Journal of Molecular Sciences, vol. 9, no. 6, pp. 978–999, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. Y. Zeng, E. J. Wagner, and B. R. Cullen, “Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells,” Molecular Cell, vol. 9, no. 6, pp. 1327–1333, 2002. View at Publisher · View at Google Scholar · View at Scopus
  97. D. Grimm, K. L. Streetz, C. L. Jopling et al., “Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways,” Nature, vol. 441, no. 7092, pp. 537–541, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. B. W. M. van Balkom, T. Pisitkun, M. C. Verhaar, and M. A. Knepper, “Exosomes and the kidney: prospects for diagnosis and therapy of renal diseases,” Kidney International, vol. 80, no. 11, pp. 1138–1145, 2011. View at Publisher · View at Google Scholar · View at Scopus
  99. H. Valadi, K. Ekström, A. Bossios, M. Sjöstrand, J. J. Lee, and J. O. Lötvall, “Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells,” Nature Cell Biology, vol. 9, no. 6, pp. 654–659, 2007. View at Publisher · View at Google Scholar · View at Scopus
  100. T. S. Chen, R. C. Lai, M. M. Lee, A. B. H. Choo, C. N. Lee, and S. K. Lim, “Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs,” Nucleic Acids Research, vol. 38, no. 1, pp. 215–224, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. M. L. Alvarez, M. Khosroheidari, R. Kanchi Ravi, and J. K. Distefano, “Comparison of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers,” Kidney International, vol. 82, no. 9, pp. 1024–1032, 2012. View at Publisher · View at Google Scholar · View at Scopus
  102. F. Barutta, M. Tricarico, A. Corbelli et al., “Urinary exosomal microRNAs in incipient diabetic nephropathy,” PLoS One, vol. 8, no. 11, Article ID e73798, 2013. View at Google Scholar
  103. O. Soubani, A. S. Ali, F. Logna, S. Ali, P. A. Philip, and F. H. Sarkar, “Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer,” Carcinogenesis, vol. 33, no. 8, pp. 1563–1571, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. Y. Li, T. G. Vandenboom II, D. Kong et al., “Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells,” Cancer Research, vol. 69, no. 16, pp. 6704–6712, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. J. Wei, Y. Zhang, Y. Luo et al., “Aldose reductase regulates miR-200a-3p 141-3p to coordinate Keap1-Nrf2, Tgfbeta1 2 and Zeb1 2 signaling in renal mesangial cells and the renal cortex of diabetic mice,” Free Radical Biology and Medicine, vol. 67, pp. 91–102, 2013. View at Publisher · View at Google Scholar
  106. H. L. A. Janssen, H. W. Reesink, E. J. Lawitz et al., “Treatment of HCV infection by targeting microRNA,” The New England Journal of Medicine, vol. 368, no. 18, pp. 1685–1694, 2013. View at Publisher · View at Google Scholar · View at Scopus
  107. Z. Li and T. M. Rana, “Therapeutic targeting of microRNAs: current status and future challenges,” Nature Reviews Drug Discovery, vol. 13, pp. 622–638, 2014. View at Publisher · View at Google Scholar